TABLE 2.
Clinical study of JAK/STAT inhibitors.
| Agent | Target(s) | Disease(s) | Phase | Status* | ClinicalTrials.gov identifier(s) |
|---|---|---|---|---|---|
| Baricitinib | JAK1, JAK2 | Rheumatoid Arthritis (RA) | Phase 4 | Recruiting | NCT05238896 |
| Atopic Dermatitis | Phase 3 | Completed | NCT03559270 NCT03435081 | ||
| Diabetic Nephropathy | Phase 2 | Completed | NCT01683409 | ||
| Psoriasis | Phase 2 | Completed | NCT01490632 | ||
| Alopecia Areata | Phase 2/3 | Active, not recruiting | NCT03570749 | ||
| Systemic Lupus Erythematosus (SLE) | Phase 3 | Completed | NCT03616964 | ||
| Pyoderma Gangrenosum | Phase 2 | Recruiting | NCT04901325 | ||
| COVID-19 | Phase 2/3 | Completed | NCT04358614 | ||
| Human Immunodeficiency Virus | phase 2 | Not yet recruiting | NCT05452564 | ||
| Dermatomyositis | Phase 3 | Recruiting | NCT04972760 | ||
| Amyotrophic Lateral Sclerosis | Phase 1/2 | Recruiting | NCT05189106 | ||
| Graft-versus-host-disease | Phase 1/2 | Active, not recruiting | NCT04131738 | ||
| Systemic Sclerosis | Phase 4 | Recruiting | NCT05300932 | ||
| Immune Thrombocytopenia | Phase 2 | Recruiting | NCT05446831 | ||
| Juvenile Idiopathic Arthritis | Phase 3 | Completed | NCT03773978 | ||
| Aicardi Goutieres Syndrome | Phase 2 | Active, not recruiting | NCT03921554 | ||
| Liver Diseases | Phase 1/2 | Completed | NCT01870388 | ||
| Arteritis | Phase 2 | Completed | NCT03026504 | ||
| Sjogren’s Syndrome | Phase 2 | Recruiting | NCT05016297 | ||
| Allergic Contact Dermatitis | Early Phase 1 | Recruiting | NCT03945760 | ||
| Vitiligo | Phase 2 | Active, not recruiting | NCT04822584 | ||
| Cutaneous Lichen Planus | Phase 2 | Recruiting | NCT05188521 | ||
| Polymyalgia Rheumatic (PMR) | Phase 2 | Recruiting | NCT04027101 | ||
| Idiopathic Inflammatory Myopathies | Phase 2 | Recruiting | NCT04208464, NCT05400889 | ||
| Chronic Kidney Diseases | Phase 2 | Recruiting | NCT05237388 | ||
| Ruxolitinib | JAK1, JAK2 | Polycythemia, Myelofibrosis, chronic Graft-versus-host disease (cGVHD), Atopic Dermatitis | FDA approved | ||
| Chronic Myelomonocytic Leukemia (CMML) | phase 2 | Recruiting | NCT03722407 | ||
| Chronic Lymphocytic Leukemia | Phase 1/2 | Completed | NCT02015208 | ||
| Lymphoma | Phase 2 | Recruiting | NCT02974647, NCT01965119 | ||
| Lichen Planus | phase 2 | Not yet recruiting | NCT05593432, NCT05593445 | ||
| Bronchiolitis Obliterans Syndrome | Phase 2 | Recruiting | NCT05413356 | ||
| Vitiligo | Phase 3 | Active, not recruiting | NCT04530344 | ||
| Chronic Hand Eczema (CHE) | Phase 3 | Recruiting | NCT05233410 | ||
| COVID-19 | Phase 2 | Unknown | NCT04414098 | ||
| COVID-19 Induced Lung Injury ARDS | Phase 2 | Completed | NCT04359290 | ||
| COVID-19 Associated Cytokine Storm | Phase 3 | Completed | NCT04362137 | ||
| Thrombocythemia and Polycythemia Vera | Phase 2 | Recruiting | NCT04644211 | ||
| Hemophagocytic Syndrome (HPS) | Phase 2 | Completed | NCT02400463 | ||
| Solid Organ Transplant Recipients with Advanced Cutaneous Squamous Cell Carcinoma | Phase 2 | Recruiting | NCT04807777 | ||
| Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | NCT03153982 | ||
| Premalignant Breast Disease | Phase 2 | Recruiting | NCT02928978 | ||
| Non-small Cell Lung Cancer cachexia | Early Phase 1 | Recruiting | NCT04906746 | ||
| Tofacitinib | JAK3, JAK1, JAK2 | Rheumatoid Arthritis (RA) | FDA approved | ||
| Psoriasis | phase 2 | Completed | NCT01831466 | ||
| Kidney Transplantation | Phase 2 | Completed | NCT00263328 | ||
| Systemic Sclerosis (SSc) | phase 1/2 | Completed | NCT03274076 | ||
| Sarcoidosis | phase 1 | Completed | NCT03910543, NCT03793439 | ||
| Systemic Lupus Erythematosus (SLE) | Phase 2 | Recruiting | NCT03288324 | ||
| Ankylosing Spondylitis (AS) | Phase 3 | Completed | NCT03502616 | ||
| Ulcerative Colitis | Phase 3 | Recruiting | NCT04624230 | ||
| Juvenile Idiopathic Arthritis (JIA) | phase 3 | Completed | NCT02592434 | ||
| Alopecia Areata | Phase 4 | Completed | NCT03800979 | ||
| Primary Sjögren’s Syndrome | Phase 2 | Recruiting | NCT05087589 | ||
| Dermatomyositis | phase 1 | Completed | NCT03002649 | ||
| Glioblastoma | Phase 2 | Recruiting | NCT05326464 | ||
| Myasthenia Gravis | Early Phase 1 | Recruiting | NCT04431895 | ||
| Psoriatic Arthritis | phase 3 | Completed | NCT03736161, NCT03486457 | ||
| COVID-19 | phase 2 | Completed | NCT04750317 | ||
| Takayasu Arteritis | Phase 4 | Recruiting | NCT05102448 | ||
| Upadacitinib (ABT494) | JAK1 | Rheumatoid Arthritis | Phase 3 | Completed | NCT02955212 |
| Psoriatic Arthritis | Phase 3 | Active, not recruiting | NCT03104374, NCT03104400 | ||
| Atopic Dermatitis | Phase 3 | Active, not recruiting | NCT04195698, NCT03569293 | ||
| Hidradenitis Suppurativa (HS) | Phase 2 | Completed | NCT04430855 | ||
| Spondyloarthritis | Phase 3 | Active, not recruiting | NCT04169373 | ||
| Juvenile Idiopathic Arthritis (JIA) | Phase 1 | Recruiting | NCT03725007 | ||
| Ulcerative Colitis (UC) | Phase 3 | Completed | NCT03653026 | ||
| Crohn’s Dsease | Phase 3 | Completed | NCT03345836, NCT03345849 | ||
| Takayasu Arteritis (TAK) | Phase 3 | Recruiting | NCT04161898 | ||
| Ankylosing Spondylitis (AS) | Phase 2 | Completed | NCT03178487 | ||
| Non-Segmental Vitiligo | Phase 2 | Active, not recruiting | NCT04927975 | ||
| Giant Cell Arteritis (GCA) | Phase 3 | Recruiting | NCT03725202 | ||
| Itacitinib (INCB039110) | JAK1, JAK2 | Plaque Psoriasis | Phase 2 | Completed | NCT01634087 |
| Myelofibrosis | Phase 2 | Completed | NCT01633372 | ||
| Non-Severe Hemophagocytosis Lymphohistiocytosis | Phase 2 | Recruiting | NCT05063110 | ||
| Advanced Hepatocellular Carcinoma | Phase 1 | Recruiting | NCT04358185 | ||
| Graft-versus-host-disease | Phase 2 | Completed | NCT03846479 | ||
| Bronchiolitis Obliterans Syndrome | Phase 1/2 | Active, not recruiting | NCT03978637 | ||
| Systemic Sclerosis | phase 2 | Not yet recruiting | NCT04789850 | ||
| Metastatic Synovial Sarcoma | Phase 1 | Recruiting | NCT03670069 | ||
| Rheumatoid Arthritis | Phase 2 | Completed | NCT01626573 | ||
| Cytokine Release Syndrome | Phase 2 | Recruiting | NCT04071366 | ||
| Filgotinib | JAK1 | Rheumatoid Arthritis (RA) | Phase 3 | Active, not recruiting | NCT03025308 |
| Cutaneous lupus erythematosus (CLE) | Phase 2 | Completed | NCT03134222 | ||
| Fistulizing Crohn’s Disease | Phase 2 | Completed | NCT03077412 | ||
| Ulcerative Colitis | Phase 3 | Completed | NCT02914522 | ||
| Ankylosing Spondylitis | Phase 2 | Completed | NCT03117270 | ||
| Lupus Membranous Nephropathy (LMN) | Phase 2 | Completed | NCT03285711 | ||
| Small Bowel Crohn’s Disease | Phase 2 | Completed | NCT03046056 | ||
| Psoriatic Arthritis | Phase 2 | Completed | NCT03101670 | ||
| Sjogren’s Syndrome | Phase 2 | Completed | NCT03100942 | ||
| Deucravacitinib | Tyk2 | Psoriasis | Phase 3 | Recruiting | NCT05478499, NCT04036435 |
| Psoriatic Arthriti | Phase 3 | Recruiting | NCT04908202, NCT04908189 | ||
| Nail Psoriasis | Early Phase 1 | Not yet recruiting | NCT05124080 | ||
| Plaque Psoriasis | Phase 3 | Recruiting | NCT04772079 | ||
| Alopecia Areata | Phase 2 | Not yet recruiting | NCT05556265 | ||
| Crohn Disease | Phase 2 | Recruiting | NCT04877990 | ||
| Ulcerative Colitis | Phase 2 | Active, not recruiting | NCT03934216 | ||
| Subacute Cutaneous Lupus Erythematosus (SCLE) | Phase 2 | Recruiting | NCT04857034 | ||
| Lestaurtinib (CEP-701) | JAK2 | Myelofibrosis | Phase 2 | Completed | NCT00494585 |
| Acute Myeloid Leukemia | Phase 2 | Completed | NCT00079482 | ||
| Neuroblastoma | Phase 1 | Completed | NCT00084422 | ||
| Polycythemia Vera | Phase 2 | Completed | NCT00586651 | ||
| Chronic Beryllium Disease (CBD) | Phase 2 | Completed | NCT00586651 | ||
| Psoriasis | Phase 2 | Completed | NCT00236119 | ||
| Prostate Cancer | Phase 2 | Completed | NCT00081601 | ||
| Ritlecitinib | JAK3 | Rheumatoid Arthritis (RA) | Phase 2 | Completed | NCT04413617 |
| Alopecia Areata | Phase 2/3 | Completed | NCT03732807 | ||
| Non-segmental Vitiligo | phase 3 | Not yet recruiting | NCT05583526 | ||
| Cicatricial Alopecia | phase 2 | Not yet recruiting | NCT05549934 | ||
| Abrocitinib | JAK1 | Atopic Dermatitis | Phase 3 | Completed | NCT04345367 |
| Prurigo Nodularis | Phase 2 | Completed | NCT05038982 | ||
| Food Allergy | Phase 1 | Recruiting | NCT05069831 | ||
| Brepocitinib | JAK1, Tyk2 | Cicatricial Alopecia | Phase 2 | Recruiting | NCT05076006 |
| Active Non-Infectious Non-Anterior Uveitis | Phase 2 | Recruiting | NCT05523765 | ||
| Dermatomyositis | Phase 3 | Recruiting | NCT05437263 | ||
| Delgocitinib | JAK1, JAK2, JAK3, Tyk2 | Atopic Dermatitis | Phase 2 | Completed | NCT03725722 |
| Frontal Fibrosing Alopecia | Phase 2 | Recruiting | NCT05332366 | ||
| Chronic Hand Eczema | Phase 3 | Recruiting | NCT05355818 | ||
| Danvatirsen (AZD9150) | STAT3 | Advanced Colorectal Carcinoma | Phase 2 | Active, not recruiting | NCT02983578 |
| Advanced Lung Non-Small Cell Carcinoma | Phase 2 | Active, not recruiting | NCT03819465 | ||
| Metastatic Squamous Cell Carcinoma of the Head and Neck | Phase 1/2 | Active, not recruiting | NCT02499328 | ||
| Fedratinib | JAK2 | Myeloproliferative Neoplasm | Phase 2 | Recruiting | NCT05177211 |
| Myelofibrosis | Phase 3 | Recruiting | NCT03952039 | ||
| OPB-31121 | STAT3 | Advanced Solid Tumors | Phase 1 | Completed | NCT00955812 |
| Hepatocellular Carcinoma | Phase 1/2 | Completed | NCT01406574 | ||
| OPB-51602 | STAT3 | Malignant Solid Tumour | Phase 1 | Completed | NCT01423903, NCT01184807 |
| Oclacitinib | JAK1 | Canine Allergic Dermatitis | FDA approved | ||
| Momelitinib | JAK1, JAK2 | Anemic Myelofibrosis | Phase 3 | Active, not recruiting | NCT04173494 |
| Peficitinib | JAK1, JAK3 | Rheumatoid Arthritis (RA) | Phase 3 | Completed | NCT03660059, NCT02305849 |
| Decernotinib (VX509) | JAK3 | Rheumatoid Arthritis (RA) | Phase 2/3 | Completed | NCT01830985 |
| AZD1480 | JAK1, JAK2 | Myelofibrosis | Phase 1 | Completed | NCT00910728 |
| Gandotinib (LY2784544) | JAK2V617F | Myeloproliferative Neoplasms | Phase 2 | Active, not recruiting | NCT01594723 |